 NRx Pharmaceuticals Inc NASDAQ: NRXP has announced an additional finding from its Phase 2b3 trial investigating Zyesami aviptadil for critically ill COVID-19 patients with acute respiratory failure. Previously announced results have focused on survival and recovery from respiratory failure at 60 days and Zyesamis role in preventing the rise in the inflammatory cytokine IL-6 cytokine storm. 